Skip to main content

colchicine

Generic: COLCHICINE·Brand: COLCHICINE, COLCRYS, Colcrys, GLOPERBA, Gloperba, LODOCO, MITIGARE, Mitigare

colchicine: 5 clinical trials tracked.

colchicine evidence translation

What we can confirm

5 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about colchicine, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence4 indications · 2 study sponsors
Clinical Trials (5)

A Phase 2, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Trial to Evaluate the Efficacy and Safety of SSGJ-613 for Prophylaxis Against Acute Gouty Arthritis Flares in Subjects Initiating Urate-Lowering Treatment.

NCT07708181·Phase 2
Not yet recruiting

Primary endpoint: Numbers of acute gout flares

InterventionalRandomizeddouble200 targetStarted 2026-08Completion 2028-04Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Colchicine to Quench the Inflammatory Response After Deep Vein Thrombosis: A Randomized Controlled Pilot Trial

NCT06440694·Phase 3·GHRS
Recruiting

Primary endpoint: Pilot Trial Primary Outcome: Recruitment Rate

InterventionalRandomizedquadruple150 targetStarted 2025-07Completion 2027-124 sites · CanadaOttawa Hospital Research Institute

Clinical Outcomes of Colchicine Therapy Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome: the MACT (Mono Antiplatelet and Colchicine Therapy) Prospective Multicenter Study

NCT06543082·Phase 4·CDTX
Recruiting

Primary endpoint: Efficacy Outcome: Net adverse clinical event

Interventionalopen490 targetStarted 2024-08Completion 2028-129 sites · South KoreaCHA University

Impact of Colchicine on Peri-Operative Major Adverse Cardiovascular Events in Patients With Prior Coronary Revascularization

NCT05618353·Phase 4
Recruiting

Primary endpoint: Major adverse cardiovascular events

InterventionalRandomizedquadruple700 targetStarted 2023-08Completion 2029-049 sites · United StatesVA Office of Research and Development

Randomised Evaluation of COVID-19 Therapy

NCT04381936·Phase 3
Recruiting

Primary endpoint: Community-acquired pneumonia: All-cause mortality (with subsidiary analyses of cause of death and of death at various timepoints following discharge)

InterventionalRandomizedopen70,000 targetStarted 2020-03Completion 2038-0916 sites · Belgium, Estonia, France, Ghana…University of Oxford